/TPST
TPST Stock - Tempest Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.12+4.70%
+$0.14 (+4.70%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.43
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TPST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.09 – $3.15
TARGET (TP)$3.59
STOP LOSS$2.87
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-2.26
52W High$13.65
52W Low$2.87
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-389,000 | N/A | N/A | N/A | $-815,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-42,026,000 | $-29,157,000 | $-34,640,000 | $-26,986,000 | $-19,298,000 |
| Net Income | $-41,843,000 | $-29,491,000 | $-35,709,000 | $-28,302,000 | $-19,118,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.50 | $-1.91 | $-3.18 | $-7.80 | $-612.56 |
Company Overview
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$14
Average Target
↑ 348.7% Upside
Now
$13
Low
$14
Average
$15
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 10th 2025 | Scotiabank | Downgrade | Sector Perform | - |
| April 10th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| March 14th 2024 | Scotiabank | Initiation | Sector Outperform | $13 |
| February 8th 2024 | Jefferies | Initiation | Buy | $15 |
Earnings History & Surprises
TPSTBeat Rate
68%
Last 19 quarters
Avg Surprise
-31.7%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$-0.79
Q4 2025
EPS Surprise History
Q1 24
+10.5%
$-4.42vs$-4.94
Q2 24
+18.2%
$-4.68vs$-5.72
Q3 24
+10.6%
$-5.46vs$-6.11
Q4 24
-10.8%
$-5.33vs$-4.81
Q1 25
-29.2%
$-4.03vs$-3.12
Q2 25
+14.8%
$-3.16vs$-3.71
Q3 25
+35.9%
$-2.07vs$-3.23
Q4 25
+75.8%
$-0.79vs$-3.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-3.52 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-3.27 | $-0.79 | +75.8% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-3.23 | $-2.07 | +35.9% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-3.71 | $-3.16 | +14.8% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-3.12 | $-4.03 | -29.2% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-4.81 | $-5.33 | -10.8% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-6.11 | $-5.46 | +10.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-5.72 | $-4.68 | +18.2% | ✓ BEAT |
Q1 2024 | Mar 19, 2024 | $-4.94 | $-4.42 | +10.5% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-7.15 | $-6.24 | +12.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-7.54 | $-7.02 | +6.9% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-8.58 | $-7.15 | +16.7% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-9.36 | $-8.19 | +12.5% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-9.88 | $-8.58 | +13.2% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-11.96 | $-10.27 | +14.1% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-14.56 | $-15.34 | -5.4% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-1.23 | $-1.12 | +8.9% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-13.65 | $-15.73 | -15.2% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-11.44 | $-99.22 | -767.3% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-5.25 | $-6.60 | -25.7% | ✗ MISS |
Latest News
Tempest Therapeutics shares are trading lower after the company announced a $4.25 million offering.
📉 NegativeBenzinga•Nov 25, 2025, 02:17 PM
Tempest Therapeutics Announces ~$4.25M Offering Of 1.2M Common Stock, 1.2M Warrants At $3.625/Share
➖ NeutralBenzinga•Nov 25, 2025, 01:03 PM
Tempest shares are trading lower after the company announced it has signed agreements to acquire Factor Bioscience's Dual-CAR T programs in an all-stock transaction.
➖ NeutralBenzinga•Nov 19, 2025, 04:21 PM
Tempest Announces Matt Angel To Assume Role Of President And CEO; Stephen Brady To Assume Role Of Chairman Of The Board Of Directors Upon Closing Of The Acquisition
📈 PositiveBenzinga•Nov 19, 2025, 03:00 PM•Also:
Tempest Therapeutics Shares Resume Trade
➖ NeutralBenzinga•Nov 19, 2025, 02:58 PM
Tempest Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -34.96%
📉 NegativeBenzinga•Nov 19, 2025, 02:57 PM
UPDATE: Tempest To Acquire Factor's Dual-CAR T Programs In All-Stock Deal, Issuing 8,268,495 Shares; Stockholders Will Be Entitled To Receive 1 Common Stock Warrant For Every Share Of Common Stock Held And Outstanding At A Date Immediately Prior To The Closing; Warrants Will Be Immediately Exercisable With An Initial Exercise Price Equal To $18.48 And Will Expire 5-Years From The Issuance Date
📈 PositiveBenzinga•Nov 19, 2025, 02:57 PM
Tempest Therapeutics Signs Agreements To Acquire Certain Dual-Targeting Chimeric Antigen Receptor-T Programs From Factor Bioscience
📈 PositiveBenzinga•Nov 19, 2025, 02:04 PM
Tempest Therapeutics Q3 EPS $(0.79) Beats $(3.27) Estimate
📈 PositiveBenzinga•Nov 5, 2025, 01:34 PM
Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%
📉 NegativeSeeking Alpha•Jun 11, 2025, 12:31 PM
Tempest Therapeutics GAAP EPS of -$3.16 misses by $0.01
📉 NegativeSeeking Alpha•May 13, 2025, 09:16 PM
Frequently Asked Questions about TPST
What is TPST's current stock price?
Tempest Therapeutics, Inc. (TPST) is currently trading at $3.12 per share. The stock has moved +4.70% today.
What is the analyst price target for TPST?
No analyst price targets are currently available for this stock.
What sector is Tempest Therapeutics, Inc. in?
Tempest Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TPST's market cap?
Tempest Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does TPST pay dividends?
No, Tempest Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to TPST for comparison